Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

98 per diluted common share, and $14.7 million, or $1.51 per diluted common share, respectively. The net loss in the years ended December 31, 2012 and 2011 included a non-cash gain on revaluation of our warrant liability of $4.5 million and $7.4 million, respectively. 
  • We had $75.4 million in cash, cash equivalents and short-term investments as of December 31, 2012, compared to $64.9 million as of December 31, 2011.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 million to $50 million.
  • Year-end cash, cash equivalents and investments are expected to be in the range of $25 million to $35 million.
  • Based on our current expectations, we believe our capital resources as of December 31, 2012 will be sufficient to fund our currently planned operations into 2015.
  • At March 7, 2013, we had 14,658,766 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended December 31,Year ended December 31,2012201120122011Collaboration revenue$
    9,780$
    ,236$
    20,095$
    5,496Operating expenses:  Research and development15,6457,47739,94821,553  General and administrative2,0421,7317,7916,230  Restructuring gain(1,657)-(1,657)-Total operating expenses16,0309,20846,08227,783Loss from operations6,2507,97225,98722,287  Other income (expense)2,147(1,596)4,8897,614Loss for the period before income taxes(4,103)(9,568)(21,098)(14,673)  Income taxes----Net loss$
    (4,103)$
    (9,568)$   (21,098)$ (14,673)Basic and diluted net loss per share$
    (0.28)$
    (0.98)$
    (1.56)$
    (1.51)Weighted average number of basic and diluted common shares14,656,7939,748,63913,522,7239,729,340Consolidated Balance Sheets(In thousands) December 31,  December 31, 20122011 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
    75,697$
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
    (Date:10/22/2014)... , Oct. 22, 2014  Recently published clinical ... bolstered the already substantial database of evidence. This data ... of Stretta therapy for sufferers of refractory ... clinical evidence supporting Stretta therapy as a safe ... that make Stretta therapy available to nearly 50 million ...
    (Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
    Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
    ... April 27, 2007 — SciClone,Pharmaceuticals, Inc. (NASDAQ: SCLN) ... for the Annual Meeting of,the American Society of ... , ,ZADAXIN® (thymalfasin, thymosin alpha 1) Poster,Presentation ... on,Thymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with ...
    ... Scientific evidence,increasingly links arterial calcification to the ... some scientists question,whether a nanoparticle can live ... in,causing disease. , ,A new Mayo Clinic ... near plaque-filled arteries in animal models. The,study ...
    Cached Medicine Technology:SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO 2Evidence of Nanoparticles Found in Plaque-Filled Arteries 2
    (Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville ... health and fitness fair ¡Vive tu vida! Get Up! Get ... nutrition for better health and wellness for people of all ... open to the public, will be held at Dean Porter ... to 1:00 pm. , “¡Vive tu Vida! Get Up! ...
    (Date:10/22/2014)... 2014 Medical Solutions , ... happy to announce that our co-founder and CFO, ... Analysts’ Staffing 100 for 2014. Anderson was also ... influential people in the staffing industry,” in 2013.     ... 13th-largest healthcare staffing company in the U.S., was ...
    (Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
    (Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
    (Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
    Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
    ... nano-sensor for better detection of Mad Cow Disease agent, ... food safety, researchers in New York are reporting development ... of the deadly prion proteins that cause Mad Cow ... detects binding of prion proteins by detecting frequency changes ...
    ... Suracell,s Italian partner, DNA Research, officially launches Suracell ... international markets expected to open soon, SOUTH ... ), the leading provider of genetically directed,personalized age ... in,a series of worldwide partnerships to bring its ...
    ... Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ), ... cosmetic treatments, earlier today announced that,it has entered ... &,Gamble Company (NYSE: PG ) to exploit ... new agreement, P&G retains a non-exclusive,license in the ...
    ... New streamlined pre-application process helps make sale of long-term care ... insurance ... Treaty Network,America Insurance Company (NYSE: PTA ) has developed ... determine whether,their clients qualify for long-term care insurance (LTCi)., ...
    ... Environment and Health & Beauty Get a New ... HowToDoThings.com, a,popular online destination that helps solve ... on diverse topics, celebrates the,world,s most popular bean ... in recognition of "Caffeine Awareness Month" in March.,HowToDoThings.com ...
    ... New information about food,and diet appears every day. ... personal endorsement of a trendy diet, news reports,about conflicting ... how do you,separate the truth from the fiction when ... Month(R), the American Dietetic Association,urges consumers to look beyond ...
    Cached Medicine News:Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 2Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 3Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 4Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 5Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 6Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 7Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 8Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 9Health News:Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally 2Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 2Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 3Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 4Health News:Penn Treaty Introduces LTCi QuickPass(SM) Program 2Health News:HowToDoThings.com Brews Up New Uses for Coffee That Will Perk You Up in Recognition of March's 'Caffeine Awareness Month' 2Health News:During National Nutrition Month and Beyond, Find the Facts on Nutrition by Focusing on the Science 2
    Unipolar Ventricular Lead...
    The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl...
    Steroid-eluting, screw-in pacing lead...
    ... The Physique leads are small profile ... active-fixation helix. With a lead body size ... tip size of 7 F, the Physique ... lead available today. Available in both straight ...
    Medicine Products: